Project Description

Clinical management with JAK inhibitors

  • Available therapies for MPNs.
  • Place and opportunities in therapy for Ruxolitinib.
  • Initial dose selection.
  • On treatment dose modifications based on safety and efficacy.
  • Practical management of Adverse Events: Anemia & Thrombocytopenia as AEs.
  • Dosing optimization strategies.
  • Efficacy in V617F positive / negative patients as well as in High or Low molecular risk patients.

Ruben Mesa, MD

Consultant Hematologist Professor and Chair Hematology and Medical Oncology- Mayo Clinic. Arizona, USA